Dose 2 YN001
Phase 2Small molecule
Dose 2 YN001 is one of 27 small molecule programs targeting Coronary Atherosclerosis. It is currently in Phase 2.
1
Indications
1
Total Trials
1
Active Trials
26
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
37 competitors in Coronary Atherosclerosis
#DrugCompanyPhaseTrials
1Crestor
AstraZenecaApproved
Colcrys
Alnylam PharmaceuticalsApproved
Precose
BayerApproved
Actos
TakedaApproved
Mounjaro
Eli LillyApproved
Januvia
ZZydus Therapeutics Inc.
Approved
Benicar
CCosette Pharmaceuticals, Inc.
Approved
Lipitor
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Approved
Altoprev
CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Approved
Tekturna
Tibotec Pharmaceuticals, IrelandApproved
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Dose 2 YN001. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 2[1]
- Company
- BBeijing Inno Medicine Co., Ltd.